



# PAOLA-1

## GINECO-OV125b/ENGOT-OV-25

Platinum, Avastin and OLAparib in eoc 1st line



# PAOLA -1 Study design



# Objectives / Stratification / Statistics

- **Primary Objective** : PFS1 according to RECIST 1.1
- **Secondary objectives** : PRO/QoI, PFS2, OS, Safety
  
- **Stratification**
  - Tumor BRCA status
  - Surgery outcome and tumor evaluation before entry
  
- **Statistics**
  - Expected PFS1 from 15 months to 21,4 months
  - 2 sided  $\alpha$ , power 90%

# PAOLA-1 : Where ?

- ▶ Study Regions:  
ENGOT Groups + Japan

- ▶ Countries:

France		
Austria		
Belgium		
Germany		
Italy	 	
Japan		
		Denmark Finland Norway Sweden
		
		Spain
		

# STUDY STATUS

- ▶ First patient screened : end of April
- ▶ Currently 7 patients screened
- ▶ Estimated First patient randomized : mid-june
- ▶ Recruitment period : 18 months
  
- ▶ Investigator's meeting : Saturday 31st May  
8-10pm – Hilton Chicago